Q&A with Family Office & Life Science Symposium
Small Cap Nation
Principal Series:
Join Small Cap Nation as we host our Family Office & Life Science Symposium at the NASDAQ MarketSite taking place on February 21, 2017.
Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com
Family Office & Life Science Symposium
Join Small Cap Nation as we host our Family Office & Life Science Symposium at the NASDAQ MarketSite taking place on February 21, 2017. You can register here.
The Family Office Investment Symposium is an ongoing series that identifies superior transition-stage private and public biotech, life science, healthcare and medical technology companies. These highlighted companies are focused on the latest disruptive technologies and relevant industry trends. The SCN symposiums are designed to connect a curated group of highly vetted companies with a purposely selected group of sophisticated investors. Small Cap Nation has designed this invite-only event to generate unparalleled discovery opportunities and exclusive networking sessions. All registrants will receive a confirmation email along with event details.
Agenda:
1:30PM Registration
2:00 PM Welcome from Small Cap Nation SymposiumIntroduction by: Hugh Austin, CEO, Small Cap Nation. Jane King: Host & Moderator
2:10-2:40PM Developing a Framework for Deploying Capital into Healthcare: Strategies to De-risk Investments While Creating Impact: A discussion providing strategies and disciplines to guide deployment of capital into various healthcare sub-sectors.
- Public companies – special situations, valuations
- Provided checklist of success criteria: quality of leadership/management, commercialization experience, corporate governance, addressable market, KOL support/SAB, rare/orphan indications, disruptive technology/therapy, global implications, milestones, execution
Andrew Schneider, Family Office Networks
Tom McKenzie, Cavendish Global
Arthur Andrew Bavelas, Family Office Insights
Steven Christmann, Christmann-Guttermann Family Office
2:40 – 3:10PM How to Differentiate Investment in Private & Public Companies in Large Disease States & Exploring the SubSectors: A moderated discussion introducing the latest innovation and technologies pursuing large disease states, within the context of committing capital to a private company versus a public company.
- How to differentiate investment in private & public companies
- Differentiated approaches to investing in cancer (public vs. private)
- Exploring the subsectors: considerations for why to invest in pharma, med tech and biotech
Jeff Geschwind, M.D., CEO Prescience Labs& Oncology KOL
Chiara Russo, Analyst, Cantor
Ramses Ertdmann, (Former EVP Corporate Affairs Pharmacyclics)
Joel S Ross, MD Founder Cogwellin
BREAK: 3:10– 3:20
3:20 – 4:20 PM The Public Opportunities
Acel RX (NASDAQ: ACRX) – Tim Morris, CFO
Amyris (NASDAQ: AMRS) – John Melo, CEO
Cellular Biomedicine Group (NASDAQ: CBMG) – Tony Liu, CEO
Dicerna (NASDAQ: DRNA) – Doug Fambrough, Ph.D., CEO & President
Hemispherics (NYSE: HEB) – Thomas Equels, M.S., J.D., CEO & President
Sensus Healthcare (NASDDAQ: SRTS) – Joe Sardano, Chmn, CEO & President
4:20 – 5:00PM The Private Opportunities
AZ Therapeutics (PRIVATE) – David Elmaleh, Ph.D., CEO
Geneius Biotech (PRIVATE) – Alfred Slanetz, Chairman & CEO
Lung Therapeutics (PRIVATE) – Brian Windsor, Ph.D., CEO
Myomo (PRIVATE) – Paul Gudonis, CEO
Prescience Labs (PRIVATE) – Jeff Geschwind, CEO / Jason Rifkin, President
5:00 – 6:00 PM Networking Cocktail Reception & One-on-One